Sexual enhancement supplement recalled over three undeclared drugs

Expanding Addyi’s approval is historic in validating women’s experiences and ensuring that millions of women suffering have real choices when it comes to their sexual health.” Historic first in women's sexual health: FDA grants approval for Addyi (flibanserin) in postmenopausal women.

Issue	Description
Efficacy Debate	Some experts question the clinical significance of benefits
Side Effect Concerns	Risks of hypotension, syncope, and severe allergic reactions
Marketing & Approval Controversies	Criticism over FDA approval process and marketing practices
Post-Marketing Surveillance	Ongoing monitoring for rare adverse events

aDepartment of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh bDepartment of Endocrinology, North East Medical College and Hospital, Sylhet, Bangladesh cDepartment of Medicine, Army Medical College Cumilla, Cumilla, Bangladesh dDepartment of Gyne & Obs, Khaliajuri Upazila Health Complex, Netrokona, Bangladesh eDepartment of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, India fDepartment of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh gDepartment of Endocrinology, CEDAR Superspeciality Healthcare, Dwarka, New Delhi, India.

• Reporting of adverse events is encouraged through the FDA MedWatch program.
• Healthcare providers should report syncope, severe hypotension, or liver injury.
• Post-marketing surveillance is critical for understanding rare, long-term risks.
• Drug utilization reviews track prescribing patterns and potential misuse.
• In case of suspected pregnancy, patients should contact their doctor immediately.
• Animal studies showed developmental toxicity at doses much higher than human dose.
• Lactation studies in animals showed excretion in milk; human data are lacking.
• Decision to breastfeed while on flibanserin requires weighing potential risks.
• The benefit for an individual patient must justify the potential risk to a fetus/infant.

Received: 19 March 2024 / Received in final form: 23 May 2024 / Accepted: 24 May 2024 The authors have no funding and conflicts of interest to disclose.

Country	Approval Status	Year
United States	Approved	2015
Canada	Approved	2016
European Union	Pending/Under review	N/A
Australia	Not approved	N/A

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Adult Dosing .

Sprout Pharmaceuticals stated that Addyi has been prescribed by more than 30,000 US health care professionals to date. The company emphasized that appropriate patient selection and counseling remain essential and that patients should consult with their physicians to determine whether treatment is appropriate. Mary Claire Haver, MD, an obstetrician-gynecologist and menopause specialist, also emphasized the broader clinical context of the approval. “Menopause does not mark the end of a woman’s sexuality, but for too long, medicine has treated it that way,” Haver said. “This FDA approval is a long-overdue recognition that postmenopausal women deserve evidence-based treatment options for low sexual desire. Supplemental Digital Content is available for this article. How to cite this article: Kamrul-Hasan ABM, Hannan MA, Alam MS, Aalpona FTZ, Nagendra L, Selim S, Dutta D.

Product	Dosage	Quantity + Bonus	Price
Viagra Soft Tabs	100mg	60 + 6 Pills	152.94€ 145.66€	Buy
Kamagra Oral Jelly	100mg	90 + 8 Sachets	303.56€ 289.10€	Buy
Cialis Original	20mg	8 Pills	61.70€ 58.76€	Buy
Viagra Original	100mg	34 + 2 Pills	163.67€ 155.88€	Buy
Cialis Generic	10mg	180 + 8 Pills	236.88€ 225.60€	Buy
Viagra Generic	100mg	120 + 6 Pills	149.50€ 142.38€	Buy
Tadalista Super Active	20mg	10 Pills	55.64€ 52.99€	Buy
Priligy Generic Dapoxetine	60mg	60 + 8 Pills	183.06€ 174.34€	Buy
Kamagra Polo	100 mg	32 Pills	125.88€ 119.89€	Buy
Viagra Generic	150mg	270 + 10 Pills	326.61€ 311.06€	Buy
Cialis Generic	5mg	360 + 10 Pills	268.08€ 255.31€	Buy

Role of flibanserin in managing hypoactive sexual desire disorder in women: A systematic review and meta-analysis.

Aspect	Details
Chemical Formula	C_20H_21F_3N_4O
Molecular Weight	370.41 g/mol
Key Functional Groups	Triazole ring, fluorinated phenyl group
Structural Type	Non-steroidal compound

Kamrul-Hasan, Department of Endocrinology, Mymensingh Medical College, Mymensingh Sadar, Mymensingh 2200, Bangladesh (e-mail: [email protected]).

Desire Starts in the Brain...

“I was in the room a decade ago when Addyi became the historic first for women’s sexual health, and I have been waiting for this moment ever since,” Rubin said. “So many of my postmenopausal patients have carried the weight of frustrating low sexual desire with no FDA-approved option to turn to. It’s a critical acknowledgment that their pleasure, their well-being, and their quality of life matter—and that science-backed care should be available to every woman, at every stage of her life.” International regulatory decisions preceded the US approval. In 2021, Health Canada authorized the use of flibanserin in postmenopausal women, a move that Sprout cited as an important step toward the current FDA action. With the expanded US indication, Addyi is now approved for women younger than 65 years, making it the first and only FDA-approved pharmacologic therapy for HSDD across this broader age range. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited.

Black Box Warnings .

The medications may be beneficial for premenopausal people who: Factors that are lined with a reduced sex drive in females include: certain health conditions, such as diabetes and heart disease The FDA-approved drugs for FSIAD can have the following side effects. The side effects of Addyi can include: those who have consumed alcohol in the last 2 hours The drug can cause severe low blood pressure and fainting in people who take it with alcohol or who have liver conditions. irritation or a rash at the injection site darkening of the skin, resulting in dark spots called hyperpigmentation on the gums, face and breasts Vyleesi may reduce the efficiency of oral medications due to slower emptying of the gastric system. It can also make drugs containing naltrexone to treat alcohol and opioid addiction less effective, so anyone taking a drug that contains naltrexone should avoid Vyleesi. Like other drugs, Vyleesi and Addyi can cause allergic reactions.

Advocacy groups

Seek immediate medical help if symptoms of an allergic reaction or anaphylaxis occur. A person should speak with a doctor before taking any supplements to boost libido. The doctor can advise on the suitabilty of the products, and they may recommend medications such as Addyi and Vyleesi. Vyleesi (bremelanotide) and Addyi (flibanserin) can help treat female sexual interest/arousal disorder (FSIAD) in premenopausal people. The FDA has not approved Viagra for use in females. The work cannot be used commercially without permission from the journal. Flibanserin, approved for the treatment of hypoactive sexual desire disorder (HSDD) in females, has demonstrated diverse therapeutic and adverse effect (AE) prospects in the extant randomized controlled trials (RCTs).

How much does Addyi (flibanserin) cost?

The FDA also advises against taking over-the-counter supplements that are marketed to boost libido. Medication may not treat all causes of low sexual desire. A person can contact a doctor for advice on suitable medications and other ways to help improve blue sex pills their libido. The FDA approved flibanserin for HSDD in women younger than 65 years, expanding access to the first nonhormonal therapy for low sexual desire. The FDA has approved Addyi (flibanserin 100 mg) for the treatment of hypoactive sexual desire disorder (HSDD) in women younger than 65 years, according to an announcement from Sprout Pharmaceuticals.

https://www.ncbi.nlm.nih.gov/pubmed/12177684Curator's Comment:&nbspDescription was created based on several sources, including https://www.drugbank.ca/drugs/DB04908

The decision expands the drug’s original indication and represents the first FDA approval specifically extending pharmacologic treatment options for postmenopausal women with HSDD. HSDD is characterized by a persistent lack of sexual interest or desire that causes distress and is not better explained by another medical or psychiatric condition. It is considered the most common form of sexual dysfunction in women, with estimates suggesting that approximately 40% of women experience symptoms consistent with low sexual desire at some point in their lives. Despite its prevalence, treatment options have historically been limited, particularly for postmenopausal women. “This milestone reflects a decade of persistent work with the FDA to fundamentally change how women’s sexual health is understood and prioritized,” said Cindy Eckert, founder and CEO of Sprout Pharmaceuticals. This meta-analysis aimed to characterize the outcomes of flibanserin use in these patients comprehensively.

i am no longer interested in masturbating

“Over the years, we’ve pushed for the science to speak louder than the stigma—and today’s approval shows how far we’ve come. I want to congratulate the FDA for recognizing what millions of women have long deserved: equitable, science-backed care at every stage of life.” Addyi was initially approved by the FDA in 2015 for the treatment of HSDD in premenopausal women. The medication is a nonhormonal, centrally acting agent that modulates key neurotransmitters involved in sexual response. Since its original approval, its safety and efficacy profile has been evaluated in extensive clinical development programs, which Sprout described as the largest and most rigorous clinical trials conducted in women’s sexual health. The current approval follows the FDA’s decision earlier this year to grant priority review status to the expanded indication.

Select a category below to learn more.

Priority review is reserved for therapies that may provide significant improvements in the treatment of serious conditions or address unmet medical needs. According to the company, the designation and subsequent approval reflect increasing regulatory attention to gaps in women’s health care. “This is a major shift in expanding awareness and access to treatment for HSDD—a condition that is both common and profoundly undertreated—and we’re grateful that the FDA has acknowledged the importance of closing this gap in women’s sexual health care,” Eckert added. Clinicians who specialize in sexual medicine and menopause care have described the expanded approval as vidalista 20mg uk an important step for patients who previously lacked FDA-approved treatment options. Rachel Rubin, MD, a urologist and sexual medicine specialist, highlighted the clinical implications for postmenopausal patients. RCTs involving women with HSDD receiving flibanserin in the intervention arm and placebo in the control arm were sought after throughout the electronic databases.

• Clinical trials excluded women with many comorbidities (e.g., unstable medical conditions).
• Real-world effectiveness in broader populations may differ from trial results.
• Patient satisfaction with treatment can vary widely.
• Some women report significant improvement in sexual desire and distress.
• Others discontinue due to side effects or lack of meaningful benefit.
• Adherence to daily dosing is a challenge for some patients.
• The bedtime dosing schedule is intended to mitigate side effects like dizziness.
• Taking it with a high-fat meal can increase absorption and side effect risk.
• Should be taken on an empty stomach, at least 2 hours after a high-fat meal.

The primary outcomes were the changes from baseline in satisfying sexual events (SSE) per month and sexual desire score per month measured using an electronic diary (eDiary).

• Flibanserin was developed by Boehringer Ingelheim, later licensed to Sprout Pharmaceuticals.
• It is considered a "female Viagra," though its mechanism differs from male erectile drugs.
• The medication is part of the growing field of female sexual dysfunction treatment.
• Most clinical trials showed a modest increase in satisfying sexual events.
• Flibanserin should be taken consistently for best results.
• It is not recommended for women who are pregnant or breastfeeding.
• Common adverse reactions include dry mouth and insomnia.
• The drug was approved after extensive clinical trials involving thousands of women.
• Long-term safety data is still being collected.

From 478 initially screened articles, data from 8 RCTs involving 7906 women with HSDD were analyzed.

Peds Dosing .

In males, an erection goes down when an enzyme called phosphodiesterase type 5 (PDE-5) breaks down. Anyone who would like to try Viagra should ask a medical professional, who may prescribe the drug off-label. Vyleesi targets melanocortin receptors, which are linked to sexual function. The drug modulates the brain pathways involved in sexual response. After 3 days of taking the medication, there is a steady level of the drug in the body.

Approval Year

However, some people do not metabolize CYP2C19, an enzyme protein, effectively, and this can cause levels of the drug to build up, resulting in side effects. Vyleesi lasts around 2.7 hours, and the average time it takes to clear the body is 6.5 hours. The drug may slow how fast the body can process other medication. Vyleesi and Addyi treat FSIAD in premenopausal people. No research has tested the drug in people during or after menopause. In premenopausal women, flibanserin 100 mg was superior to placebo in improving the number of SSE per month (mean difference, MD 0.69, 95% CI [0.39, 0.99]), eDiary sexual desire score (MD 1.71, 95% CI [0.43, 2.98]), Female Sexual Function Index (FSFI) desire domain (FSFI-d) score (MD 0.30, 95% CI [0.29, 0.31]), FSFI total score (MD 2.51, 95% CI [1.47, 3.55]), Female Sexual Distress Scale-Revised (FSDS-R) Item 13 score (MD −0.30, 95% CI [−0.31, −0.29]), and FSDS-R total score (MD −3.30, 95% CI [−3.37, −3.23]).

• Flibanserin, a serotonin receptor modulator, was initially investigated for depression.
• Its approval marked a historic moment in treating female sexual dysfunction.
• The medication's side effects necessitate careful patient education.
• Efficacy is often supported by patient-reported improvements in desire.
• It does not function as an aphrodisiac but affects brain chemistry.
• Flibanserin therapy requires adherence to dosing instructions.
• Women with low libido due to other health issues may not benefit from it.
• Its role is to complement behavioral or psychological therapy if needed.
• Research continues into better options for treating female hypoactive sexual desire.